Bot Image, Inc. Achieves UKCA Certification for ProstatID® Software
This certification opens the United Kingdom market for the first FDA-cleared AI platform for prostate MRI interpretation.
OMAHA, Neb. – Bot Image, Inc., a leading name in AI-powered diagnostic imaging, proudly announces its flagship software, ProstatID®, has successfully received UKCA certification under the European Union's Medical Device Regulation (EU) 2017/745. This achievement marks a significant milestone in the company's journey toward global expansion.
The certification, granted by Intertek Medical Notified Body AB, validates that Bot Image's Quality Management System and product design comply with all UKCA safety and performance standards. This assurance reflects the company’s dedication to maintaining high-quality standards in its healthcare solutions.
ProstatID® utilizes cutting-edge artificial intelligence technology to automatically detect, segment, and classify prostate lesions found in MRI scans. Moreover, it integrates seamlessly with an increasing number of FUSION Guidance and Treatment Systems. This helps enhance diagnostic accuracy while facilitating effective communication between radiologists and interventionalists. The platform is tailored to complement routine clinical workflows, providing essential support for biopsy decisions through its standardized lesion mapping and probability scoring system, ultimately generating a 3D Prostate Cancer Estimation Map.
“Achieving CE Mark under the new MDR framework highlights Bot Image's ongoing commitment to quality, regulatory compliance, and patient safety,” stated Dr. Randall W. Jones, CEO of Bot Image, Inc. He emphasized that their European and UK partners can implement ProstatID® with confidence, knowing it meets the highest regulatory standards globally.
In light of this certification, Bot Image will commence the onboarding of European, UK, and other regional distributors and clinical partners. This is to expedite the deployment of ProstatID® across hospitals and diagnostic centers, ensuring that patients have access to the latest advancements in prostate cancer detection.
Bot Image, Inc. is recognized for developing AI-driven diagnostic imaging solutions that enhance radiologic accuracy and standardization. Its flagship product, ProstatID®, is celebrated as the first FDA-cleared, CE, and UK-certified AI software designed for prostate MRI interpretation and lesion classification. This tool empowers healthcare providers to detect clinically significant prostate cancer more reliably and earlier.
The company remains dedicated to improving patient outcomes by leveraging technological advancements in healthcare. As it moves forward, Bot Image, Inc. strives to collaborate with leading distributors to ensure the widespread availability and utilization of ProstatID® in clinical practices.
Frequently Asked Questions
What is the significance of the UKCA certification for Bot Image, Inc.?
The UKCA certification allows Bot Image to market and distribute its ProstatID® software in the UK, enhancing its position in the medical imaging field.
What technologies does ProstatID® employ?
ProstatID® uses advanced AI techniques to detect and classify prostate lesions from MRI scans efficiently.
Who can benefit from Bot Image's ProstatID® software?
Clinicians and patients can both benefit from ProstatID® as it helps in early detection and diagnosis of prostate cancer.
What steps is Bot Image taking post-certification?
The company plans to onboard distributors and clinical partners rapidly to increase deployment of ProstatID® across various healthcare facilities.
How does ProstatID® enhance clinical workflows?
By providing standardized lesion mapping and probability scores, ProstatID® supports better biopsy decision-making and integrates smoothly into existing clinical workflows.
